Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy

Next Previous
Trial Profile

Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2019

At a glance

  • Drugs BI 690517 (Primary) ; Eplerenone
  • Indications Diabetic nephropathies
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim

    • Most Recent Events

    • 20 Aug 2018 Planned End Date changed from 30 Jun 2019 to 30 Dec 2019.
    • 20 Aug 2018 Planned primary completion date changed from 30 Jun 2019 to 30 Dec 2019.
    • 18 Apr 2018 Planned number of patients changed from 126 to 105.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top